The concept of biological identity has been traditionally a central issue in immunology. The assumption that entities foreign to a specific organism should be rejected by its immune system, while self-entities do not trigger an immune response is challenged by the expanded immunotolerance observed in pregnancy. To explain this "immunological paradox", as it was first called by Sir Peter Medawar, several mechanisms have been described in the last decades. Among them, the intentional transfer and retention of small amounts of cells between a mother and her child have gained back attention. These microchimeric cells contribute to expanding allotolerance in both organisms and enhancing genetic fitness, but they could also provoke aberrant alloimmune activation.

Understanding the mechanisms used by microchimeric cells to exert their function in pregnancy has proven to be challenging as per definition they are extremely rare. Profiting from studies in the field of transplantation and cancer research, a synergistic effect of microchimerism and cellular communication based on the secretion of extracellular vesicles (EVs) has begun to be unveiled. EVs are already known to play a pivotal role in feto-maternal tolerance by transferring cargo from fetal to maternal immune cells to reshape their function. A further aspect of EVs is their function in antigen presentation either directly or on the surface of recipient cells. Here, we review the current understanding of microchimerism in the feto-maternal tolerance during human pregnancy and the potential role of EVs in mediating the allore cognition and tropism of microchimeric cells.

Keywords: cross-dressing, immunotolerance, microchimerism, pregnancy, extracellular vesicles (EV), allore cognition

INTRODUCTION

The Nobel Prize Laureate Sir Peter Medawar has become known for the formulation of the so-called immunological paradox of pregnancy. He found it surprising that, despite expressing foreign paternal antigens, the fetus remains in the mother’s uterus instead of being rejected in the way that a skin graft of paternal tissue would be (1, 2). He proposed three mechanisms by which the fetus could avoid recognition by the maternal immune system: the anatomical separation between mother and fetus by the placenta, the immaturity of fetal antigens which impairs their ability to elicit a maternal
immune response, and the immunological inertness of the maternal immune system during pregnancy (3, 4). Medawar’s work has set the first milestone in the study of reproductive immunology, but despite his efforts and those of several medical scientists throughout the last decades, the mechanisms that govern feto-maternal tolerance are still only partly understood.

During normal human pregnancy, a natural bidirectional immune regulation allows an intimate contact between maternal and fetal cells at the maternal-fetal interface in a way that a state of immune non-reactivity specific to particular antigens is established. Thereby, the developing immune system of the fetus tolerates protein products derived from polymorphic genes that are expressed by the mother but are not inherited, so-called non-inherited maternal antigens (NIMAs), while the maternal immune system tolerates the inherited paternal antigens (IPAs) expressed by the fetus (5, 6).

Although the placenta represents an important physical barrier between mother and fetus, it is permeable to a multitude of signal substances and cellular types which also contribute to the establishment of immune tolerance. Small quantities of both, mature and progenitor cells can cross the placenta in a two-way cell trafficking. These cells are known as microchimeric cells and play a key role in the regulation of alloresponses towards NIMAs and IPAs (5). Additionally, the communication between placental cells and maternal immune cells mediated by extracellular vesicles (EVs) is one of the mechanisms involved in allotolerance that is a current research focus. EVs secreted by fetal tissues have the potential to transfer fetal proteins and nucleic acids to maternal cells reshaping their function. Here, we review the current understanding of microchimerism in the feto-maternal tolerance during human pregnancy and the role of EVs in mediating alloresponses, cell trafficking, and tropism of microchimeric cells.

HISTORY OF MICROCHIMERISM

Back in 1945, Ray Owen reported the presence of two distinct blood groups in fraternal twin cows: their own and that of their twin (7). To explain this, he proposed a cell interchange between the bovine twin embryonal cells in utero, ancestral to the erythrocytes of the adult animal. The exchanged cells could become established in the hematopoietic tissues of their co-twin hosts, providing a source of blood cells distinct from those of the host, presumably throughout its life, which is the conceptual foundation of acquired immunological tolerance (7). A second publication of the same group years thereafter stated that the actively acquired Rh tolerance to Rh antigens displayed by Rh-negative women was related to their Rh-positive mothers. The possible explanation was the prenatal exposure to Rh antigens or Rh-positive cells derived from the mother (8).

Owen’s research was picked up by Burnet and Fenner as evidence of a phenomenon they named “tolerance”, placing it in the context of the “self or non-self” hypothesis whereby an organism recognizes “self” and actively defends against pathogens and tissues that are non-self (9, 10). This hypothesis was also tested by Sir Medawar andBillingham by inoculating fetuses of one mouse strain with cells from a second and later in mice adulthood, performing skin homografts from the original donor strain. These grafts were accepted, but those from a third, unrelated mouse strain, were rejected, agreeing with the fact that “self” is defined during embryonic development as Burnet and Owen had hypothesized (10, 11). Contemporarily, the British physician Dunsford found two separate blood types in the blood of a donor who had a twin brother that had died young; a phenomenon he called “blood group chimera” (12, 13). These studies helped lay the groundwork for understanding the process by which two different cell populations can be found in an individual. This became a fundamental discovery in immunology, providing new ideas for organ transplantation but it also resulted fundamental in understanding human pregnancy as actively acquired tolerance that may occur naturally by the incorporation of maternal cells into a fetus during normal development (11). These studies also set the definition of chimera as an organism whose cells derive from two or more distinct zygote lineages (14), which continues to be the meaning of the term at present times.

PREGNANCY-DERIVED MICROCHIMERISM

Currently, microchimerism is understood as the presence of less than 1% allogeneic cells or DNA housed by an individual or an organ (5, 15). Tissue microchimerism is considered to be primarily pregnancy-derived, as a bidirectional cross-placental cell trafficking occurs between fetus and mother. The decidua-trophoblast interface plays a permissive role allowing stem cells and leukocytes, among others, to be transferred from maternal tissues to fetal tissues giving rise to maternal microchimerism, and from fetal tissues to maternal tissues generating fetal microchimerism (5, 15–18). Cell-free fetal DNA can be detected in maternal blood from the fourth week of gestation (19, 20), increasing in concentration as pregnancy progresses, with a sharp increase over the last 8 weeks of pregnancy (21), but becoming undetectable at day 1 after delivery, implying that its presence is limited to the current pregnancy (22). Conversely, pregnancy-derived microchimerism has proven to be long-lasting as a small number of maternal cells persist in her offspring until adulthood, and fetal cells can be found in the mother decades after parturition (23–29). Further, microchimerism is asymmetrical, as more fetal cells are transferred to the mother - than maternal cells to the fetus (15, 16, 30, 31). Yet, the microchimeric cells seem to be more decisive for the development of the fetus than for the mother possibly due to its maternal immune system (32).

The transfer of fetal material into the maternal system was first identified in 1893 as the presence of multinucleated cells with characteristic morphology of placental cells in diverse tissues of pregnant women who died from eclampsia (33). Nowadays, it is proven that the number of fetal microchimeric cells rises in the maternal body according to the gestational age. They consist of numerous cell types such as trophoblast cells, lymphocytes, hepatocytes, erythroblasts, and mesenchymal progenitor stem cells (30). In humans, fetal microchimeric cells
infiltrate maternal tissues as early as seven weeks of gestation, differentiate, replicate and proliferate therein (19). In mice, fetal microchimeric cells appear detectable in the mother in the second week of pregnancy (34–36). Remarkably, the distribution of fetal microchimeric cells in the organs of pregnant women is not homogeneous, with the lung being the most chimeric organ followed by the spleen, liver, kidney, brain, and heart (37). Combining results from humans describing the specific localization of fetal cardiomyocytes in the maternal heart (24) and from mice locating fetal cells in maternal lungs, spleen, heart, liver, kidney, and brain (36), suggest the existence of specific mechanisms driving fetal cell tropism.

Likewise, maternal cells expressing surface markers of T and B lymphocytes, and leukocytes, leukocytes have been found in fetal tissues from the second trimester of pregnancy (38), and in immunocompetent adult offspring (25). Yet, some questions are still raised related to their involvement in the context of tolerance induction, inflammatory and autoimmune disorders in the offspring (36, 38–41).

During pregnancy, maternal microchimerism induces fetal allotolerance towards NIMAs, whereas fetal microchimerism is associated with maternal tolerance towards IPAs (36, 39–41). These effects could become long-lasting on the fetal immune system, while they seem to be only temporary on the maternal side (42, 43). The majority of NIMAs and IPAs are encoded by polymorphic genes belonging to the major histocompatibility complex (MHC) class I and II (5, 44). These molecules define the degree of maternal-fetal mismatch and the immune response against non–self tissues or allogeneic products.

In a normal immune scenario, microchimeric cells can be recognized and eliminated by the host immune system, but during pregnancy, a set of immunological adaptations is triggered to guarantee allotolerance both locally and systemically (4, 29, 45). On cellular level, the generation of Treg cells plays a fundamental role in development of immune tolerance. It occurs upon stimulation of thymus-derived naive CD4+CD44low cells with cell-extrinsic stimuli including pregnancy-related hormones, such as progesterone and glucocorticoids. Transforming growth factor β - TGF-β, TGF-Fβ, and semiallogeneic fetal antigens (46). A potential mechanism of immune tolerance driven by fetal antigen-specific Treg cells is the suppression of decidual inflammation (46). It has been proposed that these cells could persist in mother tissues as “memory cells” and can expand in subsequent pregnancies enforcing fetal immune tolerance (46).

Also CD8+ regulatory or suppressor T cells may contribute to fetal tolerance [summarized in (46)], which is more pronounced in later pregnancy (47, 48). In mice, proliferation of CD8+ T cells increases at midgestation in mice, simultaneously with increased detection of systemic fetal antigens (49). CD8+ T regulatory or suppressor cells may reduce antibody production in B cells (50).

Additionally, alike malignant, microchimeric cells have developed strategies to invade normal tissue including blood vessels and to avoid destruction by the host immune system by acquiring surveillance and adaptive properties for immune evasion (4). This is partly caused by unique, specific subsets of HLA molecules on trophoblast cells: syncytiotrophoblast (STB) and villous cytotrophoblast lack all MHC Class I and MHC Class II molecules, so that T cells cannot bind to the main placental interface. Although invasive extravillous trophoblast cells (EVT) do express HLA class I, they lack HLA-A and HLA-B antigens. Instead, they express the non-classical HLA-E, HLA-F, and HLA-G. Likewise, EVT lack MHC Class II antigens so they cannot act as antigen presenting cells (APC) initiating direct allore cognition by CD4+ T helper cells (4, 51). This non-classical pattern of HLA expression partly explains the maternal immunotolerance to paternal HLA molecules in the fetus (4).

Additional mechanisms to avoid maternal rejection include the expression of HLA-G receptor ILT2 by decidual T cells, which after recognition of fetal expressing HLA-G cells, drives a tolerogenic response. HLA-G also inhibits cytolytic T cell functions (52), and some isoforms of HLA-G could be transported from trophoblast to maternal immune cells via EVs, which can induce immune tolerance (53) or alter immune cell proliferation. Likewise, via specific ligands dNK cells are also modulated by non-classical HLA patterns on EVT, which switch their cytotoxic function to a tolerogenic behavior (4, 54, 55). The mechanisms of maternal tolerance induction to other microchimeric cells than trophoblast cells are still unknown.

It has been proven that the exposure of the fetal immune system to NIMAs by placental cell trafficking gives rise to an early NIMA-specific regulation through the induction and maintenance of allospecific CD4+CD25+ regulatory and CD8+ T cells during fetal life (5, 56, 57). These cells produce TGF-β an immune regulatory cytokine that suppresses the anti-NIMA response of fetal T effector cells, mitigating maternal–fetal conflict to enforce tolerance (7, 56, 57). Other functional roles that may be partially attributable to pregnancy-derived microchimerism include the amelioration of autoimmune disorders in women with a higher number of prior pregnancies (46, 58, 59), the replacement of injured human and murine maternal cells by fetal microchimeric cells that migrate to the site of damage and proliferate locally (60–65), and the potential adaptation of the maternal breast physiology and induction of milk supply suggested by the presence of fetal microchimeric cells (66, 67). Likewise, maternal cells may support fetal immune cell development, these potential protective effects of maternal microchimeric have been evidenced in mice by the presence of maternal cells in primary and secondary lymphoid organs before the fetal immune system is fully developed in healthy and immune-deficient offspring (29, 56). In humans this has been suggested by the presence of expanded populations of circulating maternal T cells which improve the health of offspring by augmenting host defense against microorganisms (68). Nevertheless, as the number of microchimeric cells is very low per definition, factors secreted by these cells should play a pivotal role in their function.

**HISTORICAL MILESTONES OF RESEARCH ON EVs in Pregnancy**

The beginning of the field of EV biology could be dated to the early research on blood coagulation, with the discovery of
Chargaff & West in the 1940s of a “particulate fraction” that sedimented at high speed and contained breakdown products of blood corpuscles with clotting potential (23, 69). It was only until the report of pioneering experiments with platelets that the presence and structure of those cell-free particles and their biological relevance began to be described. In 1967, Peter Wolf published electron microscopy images of a particle-like material originating from platelets, which could be high-speed sedimented and was distinguishable from intact platelets. These particles named “platelet dust” are currently known as EVs (70). Later in 1971, Neville Crawford published further images of EVs, this time being named “microparticles”, described partially their cargo, and suggested that EVs originated either in the surface membrane or within the intracellular membrane structures (71). Over the following decade and with the parallel improvement of analytic techniques, the biogenesis of different populations of EVs was described (72, 73) and the nomenclature of EVs including the term exosomes started to be coined (74, 75).

Summarizing the study of EVs in the context of pregnancy is also challenging due to the heterogeneous nomenclature used in the first studies. It can be argued that it dates back to 1974, when a simple procedure was proposed to obtain "membrane-bound bodies" from human placental villous by mechanical disruption (76). This method with minor modification is still in use for the isolation of EVs from placenta explants. Following that discovery, several groups reported both stimulatory and suppressor immune responses upon the treatment of mixed lymphocyte cultures with these preparations, which suggested their role in the regulation of immune responses and maternal allogeneic recognition during pregnancy (77, 78). Probably, one of the breakthrough events in the field was the finding of placental EVs in the maternal peripheral plasma, and the elevated levels in women suffering of Preeclampsia (PE) (79). This suggested a role of EVs in the systemic alterations for immune tolerance during pregnancy but also opened the field to the use of EVs as biomarkers for pregnancy pathologies.

In 2005 the first EV meeting took place, and since then there are regular meetings of the formed International Society for Extracellular Vesicles (ISEV) housing thousands of participants working in the study of EVs in different contexts including pregnancy. The ISEV endorses the description of EV as the generic term for particles naturally released from cells, which are delimited by a lipid bilayer, do not contain functional nucleus and cannot replicate (80). Cumulative evidence has demonstrated that EVs contribute to the transfer of functional elements, which constitutes a pivotal mechanism of cell-cell communication (81). EVs carry functional molecules including lipids, proteins, RNA (mRNA, miRNA, IncRNA), as well as DNA molecules (frequently related to pathological states) (81–84). EVs are released in an evolutionarily conserved manner by cells ranging from organisms such as prokaryotes to higher eukaryotes and plants. Based on their physical characteristics such as size and density, or specific markers of the intracellular origin, different EV subtypes can be defined (80). Depending on their biogenesis, three main EV populations have been described: Apoptotic bodies, which are released by plasma membrane blebbing occurring during apoptosis; microvesicles (also known as microparticles or ectosomes), which include vesicles of different sizes that are released from the plasma membrane; and exosomes, which are generated from intraluminal vesicles (ILV) by invagination of the endosomal membrane and accumulate in multivesicular bodies (MVB). Upon fusion of MVB with the plasma membrane, exosomes are released into the extracellular environment (85–87). This classification often overlaps with that by size because small (sEVs; <200nm) and medium/large EVs (m/lEVs; >200nm) are in most cases enriched fractions of exosomes and microvesicles, respectively (80). To identify and isolate trophoblast-derived EVs, specific placenta markers such as placental alkaline phosphatase (PLAP) (88), syncitin-1/2 (89), and HLA-G (90) are used. Likewise, tetraspanin CD63, ALIX, and TSG101 are considered general markers for exosomes as they localize predominantly to late endosomes and play an important role in sorting ILV (91, 92). Nevertheless, there is still a lack of appropriate and ubiquitous markers to differentiate other EV types and trace their cellular origin.

**EVs as Mediators of Immunological Adaptations During Pregnancy**

The human placenta releases rising concentrations of EVs during pregnancy, which are distributed to other organs and cells (93). The major producer of placental EVs is the STB covering the maternal villi and directly in contact with the maternal bloodstream (79). The STB also releases a particular population of large vesicles denominated syncytial nuclear aggregates (SNAs) containing fetal DNA, RNA, and organelles (94, 95). A cross-talk between the placenta and the maternal immune system is established via EVs, as placenta-derived EVs are incorporated by neighboring and distant maternal immune cells (96–99), while EVs produced by maternal immune cells modulate placental responses (100, 101).

Studies on placental EVs have characterized their surface and internal cargo revealing the presence of immunomodulatory factors [e.g. Fas ligand, TRAIL (102)], minor histocompatibility antigens [e.g. RPS4 (103)], glycoproteins [e.g. syncytin-1 (89)] and miRNAs (104), among others. Transfer of these signals from fetal tissues to maternal T cell, NK cell and macrophages via EVs may influence maternal immune responses and induce epigenetic reprogramming (Figure 1). Uptake of placental EVs in *in vitro* has been demonstrated to occur in nearly every tested cell, and in most cases, it has been associated to measurable effects, however this can be different when other cell types and signals are also present as it is the situation in *in vivo* (106–109). Recent studies have suggested that the EV uptake ratio could be cell-dependent with some cells such as macrophages and mature dendritic cells incorporating more EVs than monocytes and immature dendritic cells (110). However, the literature is heterogeneous when comparing other cell populations: a study reported T lymphocytes incorporating more placental-IEVs than B and NK cells (90), while in a second study, uptake of trophoblast-derived IEVs and sEVs is higher in NK compared
to T cells (107). Standardization of the sample collection, isolation, and characterization protocols will allow comparisons between studies to clarify the specificity and mechanisms of placental- and trophoblast-EV uptake by immune cells.

The function of placental EVs remains largely unclear but most of the studies report their involvement in immune responses related to induction of immune tolerance by different mechanisms. Most of the immunoregulatory surface molecules of the STB have been detected on its EVs where they are supposed to fulfill similar functions. In the following we list several examples that have been investigated. Trophoblast-derived EVs containing FasL might eliminate activated maternal T cells (102, 111). Human placenta explants release exosomes bearing ligands (MHC class I chain-related (MIC) proteins A and B, UL-16 binding proteins) of the NKG2D receptor on NK cells, cytotoxic T cells and γδ T cells. Binding of the ligands to NKG2D leads to reduced in vitro cytotoxicity without affecting the perforin-mediated lytic pathway (97).

Furthermore, placental exosomes suppress in T cells the expression of CD3-zeta chain and Janus kinase 3 (JAK3) but induce suppressor of cytokine signalling 2 (SOCS2) which may favor the expansion of lymphocytes with suppressive phenotypes, such as Treg cells (112).

Previously, we have shown that EVs enriched from choriocarcinoma cell lines transfected with a specific miRNA carry large amounts of this miRNA. Upon co-incubation with T and NK cells in vitro, the presence of specific miRNAs is able to influence their proliferation. This suggests a specific role of EVs depending on their specific cargo (107, 113). Specific features of EVs seem to be also involved in pathological conditions. A recent study reported a different effect for STB-derived small and large EVs, which upregulate pro-inflammatory cytokines in THP-1 macrophages when isolated from normal pregnancy and further increase significantly when isolated from serum of patients with PE (114). More specific effects of placental EVs on immune cell populations have been reviewed in detail previously (55, 98, 114, 115) and will not be further addressed here.

An additional aspect of EVs in feto-maternal tolerance is their function in the antigen presentation (Figure 1). This can occur either directly via MHC-peptide complexes on the EV surface, or indirectly via MHC cross-dressing of antigen (Ag)-presenting cells (APCs), a process that refers to the acquisition of intact MHC molecules pre-loaded with antigen (Ag)-derived peptides by leukocytes, in particular APCs (116). These mechanisms are of interest in the establishment and maintenance of pregnancy-derived microchimerism and will be described in detail in the next section.

CONCEIVABLE MECHANISMS OF MICROCHIMERISM-INDUCED ALLORECOGNITION AND IMMUNOTOLERANCE INVOLVING EVS

Classically, there are two distinct and non-exclusive mechanisms used by host immune cells to recognize alloantigens: the indirect and direct pathways (Figure 2). In the direct pathway, antigen presenting cells (APC) from the graft (in the context of
pregnancy the embryo/fetus) present alloantigen complexes via MHC Class I and Class II that are recognized respectively by CD8 and CD4 T cells CD8+ and CD4+ T cells of the host (the mother). In the indirect pathway, graft alloantigens (typically MHC antigens) are internalized by host APC (mostly dendritic cells), processed, and presented as peptide fragments associated to host MHC molecules for recognition by its T cells (117). Direct and indirect allorecognition pathways are poorly studied in pregnancy, being a unique situation where an allogeneic tissue escapes rejection despite extensive contact with the host. Data from mouse models suggest that maternal T cells recognize fetal antigens through the indirect mechanism, indicating that T cell response results from the uptake and processing of fetal antigen by maternal APCs (118). However, in the context of microchimerism, it is valid to speculate that a T cell response could be also induced by antigen presentation by migratory fetal cells themselves or by the shedding of fetal MHC complexes and their subsequent uptake and retention as intact molecules on the cell surface of maternal APCs (5, 119).

Recently, it has been demonstrated that intact antigens can be transferred between different cell types including T cells, macrophages, B cells and DCs. DCs can capture and retain unprocessed antigen and can transfer it to naive B cells to initiate a specific response (120, 121). This evidence raises the possibility that presentation and recognition of intact alloantigens may also occur on the surface of host APCs without the use of the so called classical mechanisms. In this semi-direct allorecognition, allogeneic MHC molecules from the graft (potentially the fetus) are acquired by host APCs, where they are not processed to allopeptides, but integrated in the membrane as conformationally intact MHC complex presenting graft antigens. This phenomenon is also known as membrane alloantigen acquisition or cross-dressing depending on the cell types involved in the exchange and the experimental model (122–124). Although host T cells recognize “intact” graft antigens, this is discussed as a distinct pathway. This results in activation of the same T cell clones as those which respond via direct pathway allorecognition (125). However, the mechanisms by which intact MHC-alloantigen complexes are transferred between cells remain poorly understood.

In the field of transplantation, early studies have suggested that cell-to-cell contact is required for host cells to acquire

**FIGURE 2** | Potential scenarios of EV involvement in the fetal allorecognition by maternal T cells. Maternal cells are shown in blue and fetal cells and EVs are shown in red. Up: Direct pathway. Fetal APCs, which secrete EVs to the intercellular space, present peptides (auto- or alloantigens) via MHC (I or II) molecules to immunocompetent maternal T cells. Middle: In the semi-direct pathway, fetal allogeneic MHC molecules (I or II) are acquired via capture and uptake of fetal cells (entire or only their cell membrane) or their secreted EVs, and then recycled and expressed on the maternal APC surface. APC can present antigens bound to fetal MHC molecules to maternal T cell receptors. The indirect pathway implies the processing of fetal proteins from EVs or cells and the presentation of deriving peptides by maternal MHC II complexes to T maternal cells. Down: Fetal-derived EVs cross-decorate maternal APCs with intact MHC-peptide complexes that can be recognized by T cells similar to the semi-direct pathway. All displayed processes involve co-stimulatory interactions between APCs and T cells which are decisive for subsequent reactions, which may be tolerogenic, immunoregulatory or -stimulatory. The figure was drawn using pictures from 105 (http://smart.servier.com/) and was based on previous revisions (5, 116).
foreign antigens, but recent publications have proposed additional mechanisms involving EVs (126, 127). These are based on the observations that despite finding only very few and in some cases no donor cells in the lymph nodes of mice after skin, heart or islet transplantation, many host cells can be found therein cross-dressed with donor MHC molecules (127). Donor EVs may represent here a source of donor MHC for T (including Treg) cell activation suggesting an additional role for EVs in the generation of an immune response against the allograft (126, 127). The intact foreign MHC molecules pre-loaded with antigen-derived peptides that are integrated into the surface of murine host DCs after uptake of graft-derived EVs, can be later recognized by host T cells, which is in essence, semi-direct allore cognition (Figure 2 middle panel) (120, 121). An additional mechanism of EV-mediated allore cognition, which does not require intracellular processing, is based on the confocal microscopy observation of a fraction of exosomes secreted by migrating mouse DCs that remain at least 4h as clusters on the surface of conventional host DCs in lymphoid organs (126). In dendritic cells, this ability to retain most exosomes on the surface is characteristic of mature but not immature cells (128). With the appropriate orientation, the donor EVs may provide the MHC complex whereas the host APCs provide the required T-cell costimulatory molecules allowing the presentation without further processing to stimulate T cells (Figure 2 lower panel) (116). The capacity of mature DCs to retain EVs organized in clusters at the surface may prevent the dilution of the specific MHC complexes and support the formation of functional immune synapses (116). This mechanism of cross-dressing has not been confirmed yet in the context of human pregnancy but some studies including ours have provided evidence of clusters of trophoblast- and placental-derived EVs attached to immune cells (107, 109, 114).

Maternal microchimerism can generate a so-called “split tolerance” in the offspring. This term has two different meanings: it may refer to simultaneous acceptance or rejection of 2 different tissues or organs from one donor or to divers reactions of different components of the immune system on the same antigen (129, 130). In pregnancy, this occurs as either an effector or a tolerogenic response in T cells depending on the origin of the antigen-presenting molecules and the presence of costimulatory factors (43). The different response to maternal microchimeric cells in a mouse model was explained through two potential mechanisms: In the first one, allomolecules from maternal microchimeric cells are released as soluble factors or via EVs as taken up by fetal DCs. After intracellular processing, antigens can be presented to fetal T cells in a self-MHC-restricted manner inducing the indirect pathway of allore cognition (43). In the second one, EV membranes containing costimulatory factors and allo-MHC molecules presenting alloantigens are integrated in fetal DC and activate T cells. Depending on the molecules and costimulatory factors present in the antigenic microdomains, either regulatory or effector T cell clones will be specifically induced, driving to split tolerance (43). Similarly, fetal microchimeric IPA+ cells may exert an allore cognition mechanism mediated by fetal-derived EVs carrying HLA-G complexes. However, there is no evidence for cross-dressing mechanism via EVs in the context of maternal immunotolerance to fetal cells yet.

EVS AS ENHANCERS OF TROPISM OF MICROCHIMERIC CELLS

Metastasizing is the process by which cancer cells are dispersed from the primary tumor and travel via blood or lymph system to form a new tumor in other tissues (131). It includes a cascade of separate events that begins with disruption of the original microenvironment, local invasion through extracellular matrix and stromal cell layers, intravasation into the lumina of blood vessels, survival in blood circulation, and subsequent arrest at distant organ sites where they extravasate into the parenchyma. Finally, metastatic cells re-start their proliferative features generating macroscopic, clinically detectable neoplastic growths, which is referred to as metastatic colonization (132–135). Studies in the field of cancer indicate that tumor-derived EVs play a significant role in the cascade of metastasis and can induce the formation of the pre-metastatic niche strengthening the tropism and establishment of new tumors (81, 136, 137).

The pre-metastatic niche is a preformed microenvironment prepared for the colonization and dissemination of cancer cells in specific organs (138, 139). It is characterized by immunosuppression as well as enhanced inflammation, angiogenesis, and vascular permeability (140, 141). EVs released by primary tumors contain proteins and other active molecules which, after internalization by cells in secondary organs, can alter these processes to generate a supportive microenvironment prior to widespread metastasis (81, 136, 137, 142). Analog to tumor-derived EVs, the specific surface and composition of fetal-derived EVs may promote cell trafficking and may induce in distant maternal organs an immunotolerant niche that allows the establishment of microchimerism (Figure 3).

EVs from placenta and their tumoral counterparts are similar in their cargo. For instance, several miRNAs known as regulators of angiogenesis, EMT, and invasion in cancer were also reported in placenta- and trophoblast-derived EVs (107, 143–145). Transfer of this miRNA cargo to endothelial cells can cause endothelial dysfunction by inducing oxidative stress and membrane damage. In breast cancer, EVs carrying miR-105 cause destruction of tight junction protein ZO-1 in recipient endothelial cells which increases vascular permeability and susceptibility for metastatic invasion (136). Exposure to EVs from first trimester human placenta affect endothelium-dependent vasodilation of mesenteric arteries in pregnant mice (146). Further, STB-derived EVs transfer miRNAs to endothelial cells affecting target gene expression therein and in pregnancy pathologies such as PE, STB-derived EVs cause extensive cell membrane damage (104). This suggests that placental EVs participate in the regulation of maternal vascular adaptations in pregnancy which is relevant for the trafficking of cells across the endothelial barriers (Figure 3).

Frontiers in Immunology | www.frontiersin.org 7 July 2022 | Volume 13 | Article 837281

Murieta-Coxca et al. Microchimerism and EVs
EV content can also be affected by additional conditions such as stress stimuli. Hypoxia-derived sEVs from human prostate cancer cells are loaded with increased amounts of TGF-β, TNF-α, and IL-6 and have elevated matrix metalloproteinase (MMP)-2/9 activity. These sEVs induce expression of ECM proteins, and promote CD11b+ cells at selected organ sites (147). During the first trimester of pregnancy, a hypoxic environment is maintained in the placenta. In response to low oxygen tension, the release of sEVs from trophoblastic cells (148) and first-trimester primary trophoblast cells (149) increases. Under hypoxic conditions, trophoblastic EVs contain a specific set of miRNAs that could potentially target genes involved in cell migration and inflammatory responses (143, 148). Uptake of these EVs may facilitate or impede vascular remodeling by inducing changes in cell migration and TNF-α secretion of endothelial cells (148).

Cancer- and trophoblast-derived EVs also share their potential to induce immunotolerance and cell migration. EVs derived from metastatic melanomas carry programmed death 1-ligand 1 (PD-L1) on their surface which interacts with programmed cell death protein 1 (PD-1) on CD8+ T cells and induces their inactivation. Stimulation of melanoma cells with IFN-γ increases the amount of PD-L1 on the surface of sEVs enhancing CD8+ T cell suppression and facilitating tumor growth (150–152). Akin to cancer EVs, those secreted by trophoblastic cells and placenta explants may modulate the immune environment by regulating, either positively or negatively, proliferation and apoptosis of T cells (107, 113, 153). EVs derived from trophoblast cells also modulate cytokine secretion and migration of macrophages, which may contribute to the immunoregulation of the recipient tissues (154, 155). Further, sEVs containing activated matrix MMP-2 2 derived from cancer cells modulate extracellular matrix by degrading collagen and fibronectin to promote cell invasion and metastasis (156). Comparably, EVs derived from trophoblast spheroids can modulate major pathways in endothelial cells including extracellular matrix organization (157).

The membrane of tumor-derived EVs expresses protein “zip-codes”, formed by specific integrin profiles, addressing specific target organs, and thus, determining metastatic organotropism (158). This may also occur during pregnancy and may explain how tropism can be directed to specific organs. Although this area is still largely unknown, a recent study has demonstrated that exogenously administered pregnancy-associated EVs traffic specifically to interstitial lung macrophages and liver Kupffer cells and associate in an integrin-dependent manner (159). Further, 24 h after intravenous injection, human placental sEVs have been localized in the lung, kidney, and liver of mice (146). This preliminary evidence supports a specific EV tropism in pregnancy to maternal organs that are most prone to harbor microchimeric cells, indicating synergies of EV and cell tropism.

CONCLUSION AND FUTURE DIRECTIONS

In the last decades, based on the observations of Peter Medawar and other scientists, several mechanisms employed by fetal cells to induce immunotolerance in the mother have been elucidated. The findings summarized in this review suggest that pregnancy-induced microchimerism and exchange of EVs play a pivotal role in modulating T cell responses. Recent studies in transplantology have proposed mechanisms linking the acquisition of graft MHC class II antigens through microchimerism and EVs, with induction of immunotolerance, and in oncology, with preparation of immunotolerant niches in distant organs to accept metastases. In the context of pregnancy, similar mechanisms may occur to induce or support immunotolerance between mother and fetus. These include tolerogenic signals contained in EVs or antigen presentation mediated by microchimeric cells and EVs, as well as...
the preparation of niches for subsequent intentional or incidental acceptance of microchimeric cells. There is evidence for some of these mechanisms, mostly in the fetus-to-mother direction, but more studies are needed to confirm they occur relevance and relevance in the bidirectional communication. Understanding these processes in pregnancy is of relevance as they are potentially altered or involved in pathologies. Further, novel technologies to modify surface and cargo of fetal EVs may selectively influence maternal APC via uptake or co-dressing and lead to the development of novel therapeutic strategies.

**AUTHOR CONTRIBUTIONS**

JM-C and DM-P contributed to conceptualization. JM-C, PF-Z, SO-P, and DM-P wrote the first draft. JM-C, PF-Z, and DM-P drafted the manuscript figures. UM participated in correcting, and critically editing the first draft. DM-P, JM-C, and UM edited and approved the final version of the manuscript. All authors approved the submitted version.

**REFERENCES**

1. Medawar PB. Peter Medawar – Nobel Lecture. NobelPrize.org. Nobel Prize Outreach AB 2022 (1960). Available at: https://www.nobelprize.org/prizes/medicine/1960/medawar/lecture/ (Accessed 2022).

2. Medawar PB. Immunological Tolerance. *Nature* (1961) 189:14–7. doi: 10.1038/189014a0

3. Male V. Medawar and the Immunological Paradox of Pregnancy: In Context. *Oxford Open Immunol* (2020) 2(1):iqa006. doi: 10.1093/oximm/iqa006

4. Rendell V, Bath NM, Brennan TV. Medawar’s Paradox and Immune Mechanisms of Fetomaternal Tolerance. *OBM Transplant* (2020) 4(1):26. doi: 10.21926/obm.transplant.2001104

5. Bracamonte-Baran W, Burlingham W. Non-Inherited Maternal Antigens, Pregnancy, and Allotolerance. *BioMed J* (2015) 38:39–51. doi: 10.4103/2319-4170.143498

6. Chen JC. Immunological Consequences of In Utero Exposure to Foreign Antigens. *Front Immunol* (2021) 12:638435. doi: 10.3389/fimmu.2021.638435

7. Owen RD. Immunogenetic Consequences of Vascular Anastomoses Between Bovine Twins. *Science* (1945) 102:400–1. doi: 10.1126/science.102.2651.400

8. Owen RD, Wood HR, Foord AG. Sturgeon P, Baldwin LG. EVIDENCE FOR ACTIVELY ACQUIRED TOLERANCE TO Rh ANTIGENS. *Proc Natl Acad U.S.A.* (1954) 40:420–4. doi: 10.1073/pnas.40.6.420

9. Burnet FM, Fenner F. Production of Antibodies. *Nature* (1950) 166:204–5. doi: 10.1038/166204a0

10. Martin A. Ray Owen and the History of Naturally Acquired Chimerism. *Chimerism* (2015) 6:2–7. doi: 10.1080/19381956.2016.1168561

11. Billingham RE, Brent L, Medawar PB. Actively Acquired Tolerance of Foreign Cells. *Nature* (1953) 172:603-6. doi: 10.1038/172603a0

12. Dunford I, Bowley CC, Hutchison AM, Thompson JS, Sanger R, Race RR. A Human Blood-Group Chimera. *Br Med J* (1953) 2:81. doi: 10.1136/bmj.2.4827.81

13. Martin A. ‘Incongruous Juxtapositions’: The Chimaera and Mrs McK. *Endeavour* (2007) 31:99–103. doi: 10.1016/j.endeavour.2007.07.003

14. Anderson D, Billingham RE, Lampkin GH, Medawar PB. The Use of Skin Grafting to Distinguish Between Monozygotic and Dizygotic Twins in Cattle. *Heredity* (1951) 5:379–97. doi: 10.1038/hdy.1951.38

15. Shrivastava S, Naik R, Suryawanshi H, Gupta N. Microchimerism: A New Concept. *J Oral Maxillofac Pathol* (2019) 23:311. doi: 10.4103/jomfp.JOMFP_85_17

16. Gammill HS, Harrington WE. Microchimerism: Defining and Redefining the Prepregnancy Context - A Review. *Placenta* (2017) 60:130–3. doi: 10.1016/j.placenta.2017.08.071

17. Hahn S, Hasler P, Vokalova L, Van Breda SV, Than NG, Hoesli JM, et al. Feto-Maternal Microchimerism: The Pre-Eclampsia Conundrum. *Front Immunol* (2019) 10:659. doi: 10.3389/fimmu.2019.00659

18. Murrieta-Coxca JM, Aengenheister L, Schmidt A, Markert UR, Ruering-Thurnherr T, Morales-Prieto DM. Addressing Microchimerism in Pregnancy by Ex Vivo Human Placenta Perfusion. *Placenta* (2021) 117:78–86. doi: 10.1016/j.placenta.2021.10.004

19. Thomas MR, Tutschek B, Frost A, Rodeck CH, Yazdani N, Craft I. The Time of Appearance and Disappearance of Fetal DNA From the Maternal Circulation. *Prenat Diagn* (1995) 15:641–6. doi: 10.1002/pd.1970150709

20. Peril B, Bianchi DW. First Trimester Prenatal Diagnosis: Fetal Cells in the Maternal Circulation. *Semin Perinatol* (1999) 23:393–402. doi: 10.1016/S0140-6736(04)16620-9

21. Lo YM, Tein MS, Lau TK, Haines CJ, Leung TN, Poon PM, et al. Quantitative Analysis of Fetal DNA in Maternal Plasma and Serum: Implications for Noninvasive Prenatal Diagnosis. *Am J Hum Genet* (1998) 62:768–75. doi: 10.1086/301800

22. Lo YM, Zhang J, Leung TN, Lau TK, Chang AM, Hjelm NM. Rapid Clearance of Fetal DNA From Maternal Plasma. *Am J Hum Genet* (1999) 64:218–24. doi: 10.1086/302205

23. Chargaff E, West R. The Biological Significance of the Thromboplastic Protein of Blood. *J Biol Chem* (1946) 166:189–97. doi: 10.1016/S0021-9258(17)34997-9

24. Bianchi DW, Zickwolf GK, Weil GJ, Sylvester S, Demaria MA. Male Fetal Progenitor Cells Persist in Maternal Blood for as Long as 27 Years Postpartum. *Proc Natl Acad U.S.A.* (1996) 93:705–8. doi: 10.1073/pnas.93.2.705.

25. Maloney S, Smith A, Furst DE, Myerson D, Rupert K, Evans PC, et al. Microchimerism of Maternal Origin Persists Into Adult Life. *J Clin Invest* (1999) 104:41–7. doi: 10.1172/JCI6611

26. Lambert NC, Erickson TD, Yan Z, Pang JM, Guthrie KA, Furst DE, et al. Quantification of Maternal Microchimerism by HLA-Specific Real-Time Polymerase Chain Reaction: Studies of Healthy Women and Women With Scleroderma. *Arthritis Rheum* (2004) 50:906–14. doi: 10.1002/art.20200

27. Donoghue K, Chan J, De la Fuente J, Kennea N, Sandison A, Anderson JR, et al. Microchimerism in Female Bone Marrow and Bone Decades After Fetal Mesenchymal Stem-Cell Trafficking in Pregnancy. *Lancet* (2004) 364:179–82. doi: 10.1016/S0140-6736(04)16631-2

28. Bayes-Genis A, Bellosillo B, de la Calle O, Salido M, Roura S, Ristol FS, et al. Identification of Male Cardiomyocytes of Extracardiac Origin in the Hearts of Women With Male Progeny: Male Fetal Cell Microchimerism of the Heart. *J Heart Lung Transplant* (2005) 24:2179–83. doi: 10.1016/j.healun.2005.06.003
29. Kinder JM, Stelzer IA, Arck PC, Way SS. Immunological Implications of Pregnancy-Induced Microchimerism. *Nat Rev Immunol* (2017) 17:483–94. doi: 10.1038/nri.2017.38

30. Simpson JL. Preimplantation Genetics and Recovery of Fetal Cells From Maternal Blood. *Curr Opin Obstet Gynecol* (1992) 4:295–301. doi: 10.1097/00001703-199204000-00016

31. Lo YM, Lau TK, Chan LY, Leung TN, Chang AM. Quantitative Analysis of Maternal Antigens in Mice. *J Reprod Immunol* (2005) 66:1–12. doi: 10.1016/j.jri.2005.02.001

32. Lapaire O, Holzgreve W, Oosterwijk JC, Brinkhaus R, Bianchi DW. Georg Lapaire O, Holzgreve W, Oosterwijk JC, Brinkhaus R, Bianchi DW. Immunological Implications of Maternal Microchimerism During and Following Fetal Pregnancy. *J Reprod Immunol* (2010) 84:117–23. doi: 10.1016/j.jri.2009.11.006

33. Georg Lapaire O, Holzgreve W, Oosterwijk JC, Brinkhaus R, Bianchi DW. Immunological Implications of Maternal Microchimerism During and Following Fetal Pregnancy. *J Reprod Immunol* (2010) 84:117–23. doi: 10.1016/j.jri.2009.11.006

34. Jonsson AM, Uzunel M, Gotherstrom C, Papadogiannakis N, Westgren M. Kinder JM, Stelzer IA, Arck PC, Way SS. Immunological Implications of Pregnancy-Induced Microchimerism. *Nat Rev Immunol* (2017) 17:483–94. doi: 10.1038/nri.2017.38

35. Kinder JM, Stelzer IA, Arck PC, Way SS. Immunological Implications of Pregnancy-Induced Microchimerism. *Nat Rev Immunol* (2017) 17:483–94. doi: 10.1038/nri.2017.38

36. Stelzer IA, Thiele K, Solano ME. Maternal Microchimerism: Lessons Learned From Murine Models. *J Reprod Immunol* (2015) 108:1–25. doi: 10.1016/j.jri.2015.06.004

37. Rijnink EC, Penning ME, Wolterbeek R, Willemus S, Zandbergen M, Van Duin SG, et al. Tissue Microchimerism is Increased During Pregnancy: A Human Autopsy Study. *Mol Hum Reprod* (2015) 21:857–64. doi: 10.1093/molhr/gav047

38. Jonsson AM, Uzunel M, Goetherstrom C, Papadogiannakis N, Westgren M. Maternal Microchimerism in Human Fetal Tissues. *Am J Obstet Gynecol* (2008) 198:325.e321–326. doi: 10.1016/j.ajog.2007.09.047

39. Dutta P, Molitor-Dart M, Bobadilla JL, Roemenburg DA, Yan Z, Torrealba JR, et al. Microchimerism is Strongly Correlated With Tolerance to Noninherited Maternal Antigens in Mice. *Blood* (2009) 114:3578–87. doi: 10.1182/blood-2009-03-213561

40. Dutta P, Burlingham WJ, Stem Cell Microchimerism and Tolerance to non-Inherited Maternal Antigens. *Chimerism* (2010) 1:2–10. doi: 10.4161/chim.1.1.12667

41. Dutta P, Burlingham WJ. Correlation Between Post Transplant Maternal Microchimerism and Tolerance Across MHC Barriers in Mice. *Chimerism* (2011) 2:78–83. doi: 10.4161/chim.18083

42. Anderson CC, Matzinger P. Immunity or Tolerance: Opposite Outcomes of Microchimerism From Skin Grafts. *Nat Med* (2001) 7:80–7. doi: 10.1038/83593

43. Breacamonte-Baran W, Florentin J, Zhou Y, Jankowska-Gan E, Haynes WJ, Zheng W, et al. Modification of Host Dendritic Cells by Microchimerism: Derived Extracellular Vesicles Generates Split Tolerance. *Proc Natl Acad Sci U.S.A.* (2017) 114:1099–104. doi: 10.1073/pnas.1618364114

44. Federici BA, Roberts DW. Experimental Laboratory Infection of Mosquito Larvae With Fungi of the Genus Cocolomyces. 1. Experiments With Cocolomyces Psorophorae Var. In Aedes Taeniorynchus and Cocolomyces Psorophorae Var. In Culiseta Inornata. *J Invertbr Pathol* (1975) 26:21–7. doi: 10.1016/0022-1812(75)90164-0

45. Mol G, Cardenas I, Abraham V, Guller S. Inflammation and Pregnancy: The Role of the Immune System at the Implantation Site. *Ann N Y Acad Sci* (2011) 1221:80–7. doi: 10.1111/j.1744-6632.2010.05130.x

46. Ack PC, Hecher K. Fetomaternal Immune Cross-Talk and its Consequences for Maternal and Offspring’s Health. *Nat Med* (2013) 19:548–56. doi: 10.1038/nm.3160

47. Blois SM, Joachim R, Kandil J, Margini R, Tometten M, Klapp BF, et al. Depletion of CD8+ Cells Abolishes the Pregnancy Protective Effect of Progesterone Substitution With Dydrogenase in Mice by Altering the Th1/Th2 Cytokine Profile. *J Immunol* (2004) 172:5893–9. doi: 10.4049/jimmunol.172.10.5893

48. Tilburgs T, Roelen DL, van der Mast BJ, Van Schip JJ, Kleijburg C, De Groot-Swings W, et al. Differential Distribution of CD4+ /CD25(bright) and CD4+/CD28(-) T-Cells in Decidua and Maternal Blood During Human Pregnancy. *Placenta* (2006) 27 Suppl A:547–53. doi: 10.1016/j.placenta.2005.11.008
and Conflict Beyond the Womb. *Bioessays* (2015) 37:1106–18. doi: 10.1002/bies.201500059

6. Bonilla-Cortivo L, Verkarre V, Lim A, Crucis-Ammengad M, Moshou D, et al. Massive Expansion of Maternal T Cells in Response to EBV Infection in a Patient With SCID-X1. *Blood* (2012) 120:1957–9. doi: 10.1182/blood-2012-04-426833

7. Chargaff E. CELL STRUCTURE AND THE PROBLEM OF BLOOD COAGULATION. *J Biol Chem* (1945) 160:351–9. doi: 10.1016/S0021-9258(18)43131-6

8. Wolf P. The Nature and Significance of Platelet Products in Human Plasma. *Br J Haematol* (1967) 13:269–88. doi: 10.1111/j.1365-2457.1967.tb08741.x

9. Crawford N. The Presence of Contractile Proteins in Platelet Microparticles Isolated From Human and Animal Platelet-Free Plasma. *Br J Haematol* (1971) 21:53–69. doi: 10.1111/j.1365-2411.1971.tb03416.x

10. Nunez EA, Wallis J, Gershon MD. Secretory Processes in Follicular Cells of the Bat Thyroid. 3. The Occurrence of Extracellular Vesicles and Colloid Droplets During Arousal From Hibernation. *Am J Anat* (1974) 141:179–201. doi: 10.1002/aja.1001410203

11. Harding C, Heuser J, Stahl P. Receptor-Mediated Endocytosis of Transferrin and Recycling of the Transferrin Receptor in Rat Reticulocytes. *J Cell Biol* (1983) 97:239–39. doi: 10.1083/jcb.97.2.239

12. Trams EG, Lauter CJ, Salem N, Heine U. Exfoliation of Membrane Ecto-Enzymes in the Form of Micro-Vesicles. *Biochim Biophys Acta* (1981) 654:63–70. doi: 10.1016/0005-2760(81)90512-5

13. Pan BT, Johnstone RM. Fate of the Transferrin Receptor During Maturation of Sheep Reticulocytes In Vitro: Selective Externalization of the Receptor. *Cell* (1983) 33:967–78. doi: 10.1016/0092-8674(83)90040-5

14. Smith NC, Brush MG, Luckett S. Preparation of Human Placental Villous Surface Membrane. *Nature* (1974) 252:302–3. doi: 10.1038/252302b0

15. McIntyre JA, Faulk WP. Trophoblast Modulation of Maternal Allogeneic Recognition. *Proc Natl Acad Sci U.S.A.* (1979) 76:4029–32. doi: 10.1073/pnas.76.8.4029

16. Goodell CW, Booth AG. The Actions of Composite Trophoblast Antigens in Microvillus Preparations Upon Cultured Maternal Lymphocytes From Early First Pregnancies. *Eur J Obstetrics Gynecology Reprod Biol* (1982) 13:15–21. doi: 10.1016/0028-2243(82)90033-8

17. Knight M, Redman CW, Linton EA, Sargent IL. Shedding of Syncytiotrophoblast Micrivioli Into the Maternal Circulation In Pre-Eclamptic Pregnancies. *Br J Obstet Gynaecol* (1998) 105:632–40. doi: 10.1111/j.1471-0528.1998.tb0178.x

18. Thery C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, Gould SJ, Raposo G. As We Wait: Coping With an Imperfect Nomenclature for Extracellular Vesicles. *J Extracell Vesicles* (2012) 1:20.3402. doi: 10.3402/jev.v1i20.20389

19. Colombo M, Raposo G, Trier C. Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles. *Annu Rev Cell Dev Biol* (2014) 30:255–89. doi: 10.1146/annurev-cellbio-101512-122326

20. Van Niel G, Charrin S, Simoes S, Romao M, Rochin L, Safig P, et al. The Tetraspanin CD63 Regulates ESCRT-Independent and -Dependent Endosomal Sorting During Melanogenesis. *Dev Cell* (2011) 21:708–21. doi: 10.1016/j.devcel.2011.08.019

21. Liu H, Kang M, Wang J, Blenkinron C, Lee A, Wise M, et al. Estimation of the Burden of Human Placental Micro- and Nano-Vesicles Extruded Into the Maternal Blood From 8 to 12 Weeks of Gestation. *Placenta* (2018) 72:73–81. doi: 10.1016/j.placenta.2018.10.009

22. Chamley LW, Chen Q, Ding J, Stone PR, Abumaree M. Trophoblast Deportation: Just a Waste Disposal System or Antigen Sharing? *J Reprod Immunol* (2011) 88:99–105. doi: 10.1016/j.jri.2011.01.002

23. Wei J, Blenkinron C, Tsai P, James IL, Chen Q, Stone PR, et al. Placental Trophoblast Debris Mediated Feto-Maternal Signalling via Small RNA Delivery: Implications for Preeclampsia. *Sci Rep* (2017) 7:14681. doi: 10.1038/s41598-017-14180-8

24. Tong M, Aghamiro VM, Chamley LW. Immunological Effects of Placental Extracellular Vesicles. *Immunol Cell Biol* (2018). doi: 10.1111/imcb.12049

25. James-Allan LB, Rosario FJ, Barner K, Lai A, Guanzon D, Mcintyre HD, et al. Regulation of Glucose Homeostasis by Small Extracellular Vesicles in Normal Pregnancy and in Gestational Diabetes. *FASEB J* (2020) 34:5724–39. doi: 10.1096/fj.201902522R

26. Holder B, Jones T, Sancho Shimizu V, Rice TF, Donaldson B, Bouqueau M, et al. Macrophage Exosomes Induce Placental Inflammatory Cytokines: A Novel Mode of Maternal-Placental Messaging. *Traffic* (2016) 17:168–78. doi: 10.1111/tra.12352

27. Rice TF, Donaldson B, Bouqueau M, Kampmann B, Holder B. Macrophage-But Not Monocyte-Derived Extracellular Vesicles Induce Placental Pro-Inflammatory Responses. *Placenta* (2018) 69:92–5. doi: 10.1016/j.placenta.2018.07.011

28. Frangsmyr L, Baranov V, Nagaeva O, Stendahl U, Kjellberg L, Mincheva-Nilsson L. Cytoplasmic Microvesicular Form of Fas Ligand in Human Early Placenta: Switching the Tissue Immune Privilege Hypothesis From Cellular to Vesicular Level. *Am J Reprod Immunol* (2012) 68:256–66. doi: 10.1111/j.1600-0891.2011.01328.x

29. Cronqvist T, Tannetta D, Mörgelin M, Belting M, Sargent I, Familari M, et al. Syncytiotrophoblast Derived Extracellular Vesicles Transfer Functional Placental miRNAs to Primary Human Endothelial Cells. *Sci Rep* (2017) 7:8558. doi: 10.1038/s41598-017-04468-0

30. Servier Medical Art. (2021). Available at: https://smart.servier.com (Accessed November 2021).
123. Herrera OB, Golshayan D, Tibbott R, Salcido Ochoa F, James MJ, Marelli-Zhang QJ, Li XL, Wang D, Huang XC, Mathis JM, Duan WM, et al. Trogocytosis–Nanovesicles Target to Specific Organs and Modulate Vascular Tone In Vivo. J Hum Reprod 2017: 32:1828–38. doi: 10.1038/jhumrep.2017.3.0829
147. Kumar A, Deep G. Exosomes in Hypoxia-Induced Remodeling of the Tumor Microenvironment. *Cancer Lett* (2020) 488:1–8. doi: 10.1016/j.canlet.2020.05.018

148. Truong G, Guanzon D, Kinhal V, Elfeky O, Lai A, Longo S, et al. Oxygen Tension Regulates the miRNA Profile and Bioactivity of Exosomes Released From Extravillous Trophoblast Cells - Liquid Biopsies for Monitoring Complications of Pregnancy. *PLoS One* (2017) 12:e0174514. doi: 10.1371/journal.pone.0174514

149. Rice GE, Scholz-Romero K, Sweeney E, Peiris H, Kobayashi M, Duncombe G, et al. The Effect of Glucose on the Release and Bioactivity of Exosomes From First Trimester Trophoblast Cells. *J Clin Endocrinol Metab* (2015) 100: E1280–1288. doi: 10.1210/jc.2015-2270

150. Raimondo S, Pucci M, Alessandro R, Fontana S. Extracellular Vesicles and Tumor-Immune Escape: Biological Functions and Clinical Perspectives. *Int J Mol Sci* (2020) 21(7):2286. doi: 10.3390/ijms21072286

151. Yin Z, Fan J, Xu J, Wu F, Li Y, Zhou M, et al. Immunoregulatory Roles of Extracellular Vesicles and Associated Therapeutic Applications in Lung Cancer. *Front Immunol* (2020) 11:2024. doi: 10.3389/fimmu.2020.02024

152. Abhang K, Mahler A, Wen Y, Ramnauth N, Mao W, Asghar W, et al. Small Extracellular Vesicles in Cancer. *Bioact Mater* (2021) 6:3705–43. doi: 10.1016/j.bioactmat.2021.03.015

153. Stenqvist AC, Nagaeva O, Baranov V, Mincheva-Nilsson L. Exosomes Secreted by Human Placenta Carry Functional Fas Ligand and TRAIL Molecules and Convey Apoptosis in Activated Immune Cells, Suggesting Exosome-Mediated Immune Privilege of the Fetus. *J Immunol* (2013) 191:5515–23. doi: 10.4049/jimmunol.1301885

154. Atay S, Gercel-Taylor C, Suttles J, Mor G, Taylor DD. Trophoblast-Derived Exosomes Mediate Monocyte Recruitment and Differentiation. *Am J Reprod Immunol* (2011) 65:65–77. doi: 10.1111/j.1600-0897.2010.00880.x

155. Atay S, Gercel-Taylor C, Taylor DD. Human Trophoblast-Derived Exosomal Fibronectin Induces Pro-Inflammatory IL-1β Production by Macrophages. *Am J Reprod Immunol* (2011) 66:259–69. doi: 10.1111/j.1600-0897.2011.00995.x

156. Hendrix A, Maynard D, Pauwels P, Braems G, Denys H, Van Den Broecke R, et al. Effect of the Secretory Small GTPase Rab27B on Breast Cancer Growth, Invasion, and Metastasis. *J Natl Cancer Inst* (2010) 102:866–80. doi: 10.1093/jnci/djq153

157. Godakumara K, Ord J, Lättekivi F, Dissanayake K, Viil J, Boggavarapu NR, et al. Trophoblast Derived Extracellular Vesicles Specifically Alter the Transcriptome of Endometrial Cells and may Constitute a Critical Component of Embryo-Maternal Communication. *Reprod Biol Endocrinol* (2021) 19:115. doi: 10.1186/s12958-021-00801-5

158. Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesis Mark M, et al. Tumour Exosome Integrins Determine Organotropic Metastasis. *Nature* (2015) 527:329–35. doi: 10.1038/nature15756

159. Nguyen SL, Ahn SH, Greenberg JW, Collaei BW, Wagena DW, Arora R, et al. Integrins Mediate Placental Extracellular Vesicle Trafficking to Lung and Liver *In Vivo* Sci Rep (2021) 114217. doi: 10.1038/s41598-021-82752-w

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Murrieta-Coxca, Fuentes-Zacarias, Ospina-Prieto, Markert and Morales-Prieto. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.